Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Disease
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Disease

Sponsor: Cancer Insight, LLC

Enrolling in our Bronx locations. This is a multi-center, prospective, randomized, single-blinded, placebo-controlled phase II trial of trastuzumab + nelipepimut-S/GM-CSF versus trastuzumab + GM-CSF alone. For patients with HER2 positive breast cancer.